VitaSpring Biomedical Reports No Revenue and Net Loss Reduction for Fiscal Year Ending January 31, 2026

VitaSpring Biomedical Co. Ltd. reported no revenue for the fiscal year ending January 31, 2026, maintaining the same status as the previous year. The company recorded a net loss of $415,368, a decrease from the $774,922 loss reported for the fiscal year ending January 31, 2025. This reduction in losses was primarily attributed to a significant decrease in operating expenses, which fell to $385,411 from $679,914 in the prior year. The decrease in expenses was driven by reductions in professional fees, stock-based compensation, and lease expenses.

The company continues to operate in a development stage, focusing on research and development of stem cell-based applications and related biomedical innovations. As of January 31, 2026, VitaSpring had total assets of $14,676, with current liabilities amounting to $4,445,244, resulting in a working capital deficiency of $4,434,717. The company has not yet commenced commercial operations, clinical trials, or incurred research and development expenses, which raises substantial doubt about its ability to continue as a going concern without additional financing.

VitaSpring's operational strategy includes the development of a stem cell bank compliant with FDA regulations and the mass production of allogeneic mesenchymal stem cells (MSC) derived from maternal placenta. The company has not yet launched any products for consumer use and is currently focused on establishing partnerships and improving its production processes. As of January 31, 2026, the company had no full-time employees, relying instead on a network of contractors and consultants.

The company has entered into a deferred payment agreement with a related party regarding $2,411,000 in accounts payable, deferring collection efforts for 24 months. Despite this agreement, the company acknowledges that it will require additional capital to fund operations over the next twelve months. Management is exploring potential financing sources, including private placements and strategic partnerships, but there is no assurance that such funding will be available on acceptable terms.

Looking ahead, VitaSpring aims to leverage its proprietary technologies in the regenerative medicine and functional wellness markets, which are projected to grow significantly. However, the company faces challenges, including the need for substantial capital, regulatory approvals, and the establishment of manufacturing capabilities. The management's ability to execute its business plan will be critical to its future success and sustainability.